

9 May 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Appointment of non-Board Interim CFO

Ondine Biomedical Inc. (AIM: OBI) announces the appointment of Alan Thomas as non-Board interim Chief Financial Officer (CFO) of the Company, effective immediately. Mr. Thomas succeeds Michael Behlke, who is stepping down from his role as CFO and COO for personal reasons. Ondine extends its sincere appreciation to Mr. Behlke for his contributions and wishes him the very best for the future.

Mr. Thomas is a highly accomplished financial executive with more than 25 years of leadership experience across public and private organizations in the healthcare, biotechnology, and infrastructure sectors, from high-growth start-ups to large multinational and public sector organizations. His prior roles include CFO at Maximus Canada Inc., a division of NYSE-listed Maximus Inc., and BC Transit, as well as Head of Finance at BC Emergency Health Services. He has also served as CFO and financial consultant to emerging and growth-stage firms including Aspreva Pharmaceuticals, Aurinia Pharmaceuticals, and Geno 10X, where he played key roles in fundraising, valuation, investor relations, and IPO preparation, notably during Aspreva's public listing.

Throughout his career, Mr. Thomas has provided strategic financial leadership and driven performance improvements through capital planning and enterprise-wide transformation initiatives. His experience includes managing large-scale budgets, implementing integrated business systems (including ERP platforms), and delivering operational efficiencies through procurement modernization and other enterprise initiatives.

Mr. Thomas will apply his deep experience in financial strategy, governance, and planning to support Ondine's next phase of growth and the continued expansion of its light-activated antimicrobial technology in key markets.

Alan Thomas, interim CFO of Ondine Biomedical, commented:

"Ondine is entering an exciting phase of development, with growing momentum behind its breakthrough technology. I'm looking forward to working with the team to help drive the Company's strategic and financial objectives forward."

COO duties will be assumed by current executive management.

Enquiries:

Ondine Biomedical Inc.

www.ondinebio.com

Carolyn Cross, CEO

Via Vane Percy & Roberts

Strand Hanson Limited (Nominated & Financial Adviser)

James Harris, Richard Johnson

+44 (0)20 7409 3494

RBC Capital Markets (Broker)

Kathryn Deegan

+44 (0)20 7653 4000

Vane Percy & Roberts (Media Contact)

Simon Vane Percy, Amanda Bernard

+44 (0)77 1000 5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products based on its proprietary

known as photodisinfection; Online has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Online's nasal photodisinfection system has a CE mark in Europe and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCSSDFWAEISEFI